Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CellCept Optimization to Reduce Coronary Heart Disease Risk in Renal Transplant Recipients
NCT01213394Phase 3Terminated
- Start
- Oct 2010
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mycophenolate mofetil in kidney transplant rejection (2 arms). Primary endpoints: Change in Framingham 10-yr age and gender adjusted score for coronary heart disease at 6 months and Incidence of a composite of acute rejection (clinically suspected and biopsy-proven), graft loss or patient death at 6 months. Started Oct 2010; status: terminated.
02
Drugs
mycophenolate mofetil
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01213394.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01213394.